Jennison Associates
JAZZ icon

Jennison Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Jennison Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-210,186
Closed -$25.9M – 612
2023
Q4 		$25.9M Sell
210,186
-260,413
-55% -$32.5M 0.02% 302
2023
Q3 		$60.9M Buy
470,599
+14,581
+3% +$1.94M 0.05% 155
2023
Q2 		$56.5M Buy
456,018
+4,753
+1% +$639K 0.05% 175
2023
Q1 		$66M Sell
451,265
-10,848
-2% -$1.6M 0.06% 151
2022
Q4 		$73.6M Buy
462,113
+16,352
+4% +$2.4M 0.07% 140
2022
Q3 		$59.4M Buy
445,761
+136,361
+44% +$20.7M 0.06% 156
2022
Q2 		$48.3M Buy
309,400
+175,916
+132% +$27.1M 0.05% 174
2022
Q1 		$20.8M Buy
133,484
+26,253
+24% +$3.81M 0.02% 347
2021
Q4 		$13.7M Buy
107,231
+2,041
+2% +$268K 0.01% 418
2021
Q3 		$13.7M Sell
105,190
-240,716
-70% -$36.4M 0.01% 415
2021
Q2 		$61.4M Buy
345,906
+107,834
+45% +$18.7M 0.04% 186
2021
Q1 		$39.1M Buy
238,072
+37,105
+18% +$6.11M 0.03% 252
2020
Q4 		$33.2M Buy
+200,967
New +$29.9M 0.02% 279
2020
Q1 		– Sell
-4,176
Closed -$623K – 664
2019
Q4 		$623K Buy
+4,176
New +$568K ﹤0.01% 575
2019
Q1 		– Sell
-4,245
Closed -$526K – 666
2018
Q4 		$526K Buy
+4,245
New +$630K ﹤0.01% 606
2016
Q4 		– Sell
-56,937
Closed -$6.92M – 821
2016
Q3 		$6.92M Sell
56,937
-549,083
-91% -$74M 0.01% 494
2016
Q2 		$85.6M Sell
606,020
-54,058
-8% -$7.97M 0.09% 196
2016
Q1 		$86.2M Sell
660,078
-3,468
-0.5% -$432K 0.09% 190
2015
Q4 		$93.3M Sell
663,546
-109,117
-14% -$15.1M 0.09% 182
2015
Q3 		$103M Sell
772,663
-3,697
-0.5% -$637K 0.11% 173
2015
Q2 		$137M Sell
776,360
-78,988
-9% -$14.2M 0.13% 149
2015
Q1 		$148M Sell
855,348
-87,825
-9% -$15.1M 0.14% 142
2014
Q4 		$154M Buy
943,173
+119,817
+15% +$19.9M 0.14% 133
2014
Q3 		$132M Sell
823,356
-324,740
-28% -$49.9M 0.12% 155
2014
Q2 		$169M Buy
1,148,096
+171,883
+18% +$23.8M 0.16% 134
2014
Q1 		$135M Buy
+976,213
New +$147M 0.13% 154

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jennison Associates's JAZZ Position: Q1 2024 in Review

Jennison Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 210,186 shares — an estimated $25.9M sold.

Jennison Associates first reported a position in JAZZ in Q1 2014 and held it in 26 quarters. The position peaked at $169M in Q2 2014. 481 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

  • Jennison Associates reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Jennison Associates sold 210,186 Jazz Pharmaceuticals shares in Q1 2024, an estimated $25.9M.
  • Jennison Associates first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 26 quarters.
  • Jennison Associates's Jazz Pharmaceuticals position peaked at $169M in Q2 2014.
  • 481 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Jennison Associates's 13F filing for Q1 2024, filed 2 May 2024.